Shanhuang Jiangzhi tablets mitigate atherosclerosis by modulating macrophage polarization and inhibiting foam cell formation via the ROS/TLR4/NF-κB pathway
Journal of Pharmacy and Pharmacology · 03.07.2026 · 78 (7)
DOI: 10.1093/jpp/rgag079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 25.07.2026. Verfasst von Yingwei Chang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Suzhou Medical College of Soochow University, Soochow University, Suzhou 215000, China. Hauptthemen laut MEDLINE: Foam Cells, Toll-Like Receptor 4, Drugs, Chinese Herbal, Atherosclerosis. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Medical and Health Science and Technology Development Project of Shandong Provincial, National Natural Science Foundation of China, Natural Science Foundation of Inner Mongolia Autonomous Region.
Abstract (Originalsprache)
Objectives
Atherosclerosis significantly contributes to global cardiovascular mortality. Macrophage polarization and foam cell formation via oxidized low-density lipoprotein uptake are key drivers of plaque progression and instability. Targeting these processes may offer a promising therapeutic approach. This study aimed to investigate the potential therapeutic effects of Shanhuang Jiangzhi tablets (SHJZT) using apolipoprotein E-deficient mice and RAW264.7 macrophage-based experimental models.
Methods
Key assays, including oxidized low-density lipoprotein-induced foam cell formation and lipopolysaccharide (LPS)-induced macrophage polarization, were performed to elucidate the regulatory effects of SHJZT, with a particular focus on the reactive oxygen species (ROS)/Toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Key findings In vivo, SHJZT treatment significantly attenuated atherosclerotic lesion development, improved lipid metabolism, and enhanced reverse cholesterol transport by regulating ABCA1 and ABCG1 expression, thereby suppressing foam cell formation. Furthermore, SHJZT promoted macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Mechanistic investigations revealed that SHJZT mitigated LPS-induced ROS production and inhibited the activation of the TLR4/NF-κB signaling cascade in vitro. Specifically, SHJZT downregulated key pathway components, including TLR4, MYD88, and phosphorylated NF-κB p65, in high-fat diet-induced atherosclerosis.
Conclusion
SHJZT exerts anti-atherosclerotic effects by modulating macrophage polarization and inhibiting foam cell formation through the suppression of ROS/TLR4/NF-κB signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Suzhou Medical College of Soochow University, Soochow University, Suzhou 215000, China.
- Department of Geriatrics, Qingdao Huangdao District Central Hospital, Qingdao 266071, China.
- Department of Anatomy, School of Basic Medicine, Shandong University, Jinan 250021, China.
- School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao 266071, China.
- Institute of Neurobiology, Binzhou Medical University, Yantai 264003, China.
- Medicine School, Qingdao University, Qingdao 266071, China.
ORCID-Profile: Xiuwen Liang
Förderung
- Medical and Health Science and Technology Development Project of Shandong Provincial
- National Natural Science Foundation of China
- Natural Science Foundation of Inner Mongolia Autonomous Region
- Clinical Medical Research and Clinical New Technology Promotion Project of Inner Mongolia Association
- Science and Technology Program of Hulunbuir
Zitieren
APA
Chang, Y., Liu, Q., Guo, Q., Huang, Z., Lv, A., Wang, L., He, H., Zhang, Y., & Liang, X. (2026). Shanhuang Jiangzhi tablets mitigate atherosclerosis by modulating macrophage polarization and inhibiting foam cell formation via the ROS/TLR4/NF-κB pathway. Journal of Pharmacy and Pharmacology, 78(7). https://doi.org/10.1093/jpp/rgag079
Vancouver
Chang Y, Liu Q, Guo Q, Huang Z, Lv A, Wang L, et al. Shanhuang Jiangzhi tablets mitigate atherosclerosis by modulating macrophage polarization and inhibiting foam cell formation via the ROS/TLR4/NF-κB pathway. Journal of Pharmacy and Pharmacology. 2026;78(7). doi:10.1093/jpp/rgag079
BibTeX
@article{Chang2026,
author = {Chang, Yingwei and Liu, Qing and Guo, Qixuan and Huang, Zimeng and Lv, Ang and Wang, Lei and He, Hongfeng and Zhang, Yuqiang and Liang, Xiuwen},
title = {Shanhuang Jiangzhi tablets mitigate atherosclerosis by modulating macrophage polarization and inhibiting foam cell formation via the ROS/TLR4/NF-κB pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {7},
doi = {10.1093/jpp/rgag079}
}
EUVIMED